Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin, and oxaliplatin during simulated Y-site administration

Journal of Oncology Pharmacy Practice

Volumn 10, Issue 4, 2004, Pages 191-195

  Trissel, Lawrence A ^a   Zhang, Yanping ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Carboplatin; Cisplatin; Compatibility; Oxaliplatin; Palonosetron; Stability

Indexed keywords

CARBOPLATIN; CISPLATIN; OXALIPLATIN; PALONOSETRON;

ANALYTIC METHOD; ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NEPHELOMETRY; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SEPARATION TECHNIQUE; TURBIDIMETRY;

EID: 13444257970     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155204jp136oa     Document Type: Article

References (10)

1. Aloxi (package insert). Bloomington, Minnesota: MGI PHARMA, INC., July, 2003.
2. Stacher G. Palonosetron (Helsinn). Curr Opin Investig Drugs 2002; 3: 1502-507.
3. Eglen RM, Lee CH, Smith WL, Johnson LG, Clark R, Whiting RL, Hedge SS. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br J Pharmacol 1995; 114: 860-66.
4. Allen LV Jr, Levinson RS, Phisutsinthrop D. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm 1977; 34: 939-43.
5. Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992; 49: 1716-19.
6. Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993; 50: 300-304.
7. Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993; 50: 2359-63.
8. Palonosetron HCl IV Injection 0.05 mg/mL and 0.15 mg/mL end product test procedure. Minneapolis, Minnesota: MGI PHARMA, Inc., undated.
9. Zhang YP, Xu QA, Trissel LA, Gilbert DL, Martinez JF. Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions. Ann Pharmacother 1997; 31: 1465-70.
10. Jerremalm E, Eksborg S, Ehrsson H. Hydrolysis of oxaliplatin - evaluation of the acid dissociation constant for the oxalato monodentate complex. J Pharm Sci 2003; 92: 436-38.